Adjuvant docetaxel for node-positive breast cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  New England Journal of Medicine

• Publication date

  2005-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA043681PMID 15930421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GE

  2005cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper
• Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

  2003cited by this paper
• 671 Phase III study comparing AT (Adriamycin, Docetaxel) to FAC (Fluorouracil, Adriamycin, Cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC)

  2003cited by this paper
• The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

  2003cited by this paper
• Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.

  2003cited by this paper
• Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

  2003cited by this paper
• Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

  2003cited by this paper
• Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

  2003cited by this paper
• Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

  2003cited by this paper
• Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

  2002cited by this paper
• Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

  2001cited by this paper
• Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study

  2000cited by this paper
• HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.

  2000cited by this paper
• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.

  1997cited by this paper
• Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

  1997cited by this paper
• Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

  1997cited by this paper
• Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

  1996cited by this paper
• Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.

  1996cited by this paper
• Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.

  1996cited by this paper
• Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

  1995cited by this paper
• Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.

  1995cited by this paper
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

  1995cited by this paper
• Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

  1995cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.

  1987cited by this paper
• Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project.

  1983cited by this paper
• A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project

  1977cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design.

  1976cited by this paper

• Do Combined Resistance and Aerobic Exercise Programs Cause an Interference Effect in Women with Breast Cancer? A Systematic Review and Network Meta-analysis.

  2026cites this paper
• Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

  2025cites this paper
• Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

  2025cites this paper
• De-escalation of axillary surgery in early breast cancer: translating ACOSOG Z0011 study into clinical practice for breast-conserving surgery patients with positive sentinel lymph node biopsy

  2025cites this paper
• A study to compare the efficacy of neoadjuvant chemotherapy in locally advanced human epidermal growth factor receptor 2 overexpressing breast cancer

  2025cites this paper
• Tolerability of a Tunisian generic Docetaxel in early breast cancer: A prospective study.

  2025cites this paper
• Synergistic Effect of Paclitaxel and Epirubicin CoadministrationInsight into the Mechanisms of Interactions with Model Breast Cancer Cell Membranes

  2025cites this paper
• Real-World Outcomes of Combination Anthracycline and Taxane Adjuvant Therapies in Early Triple-Negative Breast Cancer: A Moroccan Retrospective Analysis

  2025cites this paper
• The Optimal Timing and Duration of Daily G‐CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy

  2025cites this paper
• Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

  2025cites this paper
• Microcurrent stimulation induces cell death in p53-mutant and 5-FU-resistant breast cancer

  2025cites this paper
• Adjuvant capecitabine in combination with docetaxel and cyclophosphamide versus anthracycline plus docetaxel and cyclophosphamide regimen in women with high‐risk, HER2‐negative breast cancer: An open‐label, randomized controlled trial

  2025cites this paper
• Repurposing Artemisinin-Based Drugs from Antimalarial to Pan-Therapeutic: Pharmacological Promise and Therapeutic Challenges

  2025cites this paper
• Disturbing microtubule-endoplasmic reticulum dynamics by gold nanoclusters for improved triple-negative breast cancer treatment.

  2024cites this paper
• Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy

  2024cites this paper
• Efficacy of Moxibustion for Cancer-Related Fatigue in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.

  2024cites this paper
• Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors

  2023cites this paper
• The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review

  2023cites this paper
• Biological Implications of MicroRNAs as Regulators and Biomarkers of Therapeutic Toxicities in Breast Cancer

  2023cites this paper
• Improving solubility of poorly water-soluble drugs by protein-based strategy: a review.

  2023cites this paper
• Doxorubicin-Induced Modulation of TGF-β Signaling Cascade in Mouse Fibroblasts: Insights into Cardiotoxicity Mechanisms

  2023cites this paper
• Assessment of Predictive Factors for Response to Neoadjuvant Chemotherapy in Breast Cancer

  2023cites this paper
• Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

  2023cites this paper
• Pregnancy-related breast cancer: 14-year experience in a tertiary institution in Hong Kong.

  2023cites this paper
• Doxorubicin-induced modulation of TGF-β signaling cascade in mouse fibroblasts: insights into cardiotoxicity mechanisms

  2023cites this paper
• Is Immediate Lymphatic Reconstruction on Breast Cancer Patients Oncologically Safe? A Preliminary Study

  2023cites this paper
• Effect of intraperitoneal docetaxel on ovarian function in mice

  2022cites this paper
• Breast cancer treatment and ovarian function.

  2022cites this paper
• Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis

  2022cites this paper
• Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer

  2022cites this paper
• Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study

  2022cites this paper
• Lymph-Venous Anastomosis for Breast Cancer-Related Lymphoedema after Docetaxel-Based Chemotherapy

  2022cites this paper
• Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

  2022cites this paper
• Clinical Practice Guidelines in Cardio-Oncology.

  2022cites this paper
• Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia

  2022cites this paper
• Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

  2022cites this paper
• Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions

  2022cites this paper
• Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

  2022cites this paper
• Novel Docetaxel-Loaded Micelles Based on all-trans-Retinoic Acid: Preparation and Pharmacokinetic Study in Rats

  2022cites this paper
• Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.

  2022cites this paper
• 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2022cites this paper
• Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer

  2022cites this paper
• The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies

  2021cites this paper
• Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.

  2021cites this paper
• Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System

  2021cites this paper
• Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

  2021cites this paper
• Survival in the Real World: A National Analysis of Patients Treated for Early-Stage Breast Cancer

  2021cites this paper
• Machine Learning for Detection of Safety Signals From Spontaneous Reporting System Data: Example of Nivolumab and Docetaxel

  2021cites this paper
• Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial.

  2021cites this paper
• Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial—EPOC 2 (JFMC49-1601-C5)

  2021cites this paper
• Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota

  2021cites this paper
• Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India

  2021cites this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cites this paper
• Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer

  2021cites this paper
• A careful reassessment of anthracycline use in curable breast cancer

  2021cites this paper
• Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

  2020cites this paper
• Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors

  2020cites this paper
• Quantifying the Mitigating Effects of Whole-Breast Radiotherapy and Systemic Treatments on Regional Recurrence Incidence Among Breast Cancer Patients

  2020cites this paper
• Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients.

  2020cites this paper
• The prophylactic and therapeutic effects of moxibustion combined with traditional Chinese medicine decoction for treating chemotherapy-induced myelosuppression in early-stage breast cancer: study protocol for a randomized controlled trial

  2020cites this paper
• Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer

  2020cites this paper
• Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer

  2020cites this paper
• Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study

  2020cites this paper
• Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

  2020cites this paper
• NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy

  2020cites this paper
• Impact of Breast Cancer Systemic Therapies on Fertility

  2020cites this paper
• The relationship between post-surgery infection and breast cancer recurrence. A systematic review.

  2020cites this paper
• Cancer of the Breast

  2020cites this paper
• The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy

  2020cites this paper
• Administration sequence for multi-agent oncolytic regimens

  2020cites this paper
• Resistance training in breast cancer patients undergoing primary treatment: a systematic review and meta-regression of exercise dosage

  2020cites this paper
• Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.

  2020cites this paper
• Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines.

  2020cites this paper
• Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer.

  2020cites this paper
• Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer.

  2019cites this paper
• Computed Tomography in Heart Failure

  2019cites this paper
• Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.

  2019cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Taxanes for adjuvant treatment of early breast cancer.

  2019cites this paper
• Effects of sodium hyaluronate compared with steroid eye drop against the degree of canalicular stenosis in breast cancer patients treated with docetaxel

  2019cites this paper
• Risk of Lymphedema Following Contemporary Treatment for Breast Cancer

  2019cites this paper
• Cardiac MRI: a Promising Diagnostic Tool to Detect Cancer Therapeutics–Related Cardiac Dysfunction

  2019cites this paper
• Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio‐Oncology

  2019cites this paper
• Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.

  2019cites this paper
• Impact of Systemic Anticancer Therapy on Fertility

  2019cites this paper
• Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing

  2019cites this paper
• Single Institution trial of anthracycline‐ and taxane‐based chemotherapy for operable breast cancer: The ASTER study

  2019cites this paper
• Adjuvant Systemic Chemotherapy for HER2-Negative Disease

  2019cites this paper
• A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy

  2019cites this paper
• Influence of the Sense of Coherence, the Doctor–Patient Relationship, Optimism and Non-Haematological Adverse Reactions on Health-Related Quality of Life in Patients with Breast Cancer

  2019cites this paper
• The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database

  2019cites this paper
• Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.

  2019cites this paper
• Impact of Baseline Cardiovascular Comorbidity on Outcomes in Women With Breast Cancer: A Real‐world, Population‐based Study

  2019cites this paper
• Adjuvant Systemic Therapy in Breast Cancer

  2019cites this paper
• Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

  2019cites this paper
• Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

  2019cites this paper
• Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa.

  2019cites this paper
• Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study

  2018cites this paper